Roche Does Not Feel Eylea Biosimilars Will Change The Status Quo
50/50 Dynamic Of Biosimilars And Brands Expected, No Step Throughs Seen Currently
Roche’s 2022-launched Vabysmo took no time at all to reach the coveted $1bn in sales, and the originator is continuing to feel optimistic about the newer-generation VEGF brand’s prospects, even as Amgen readies the launch of the first US biosimilar to Eylea.
